peter md semaglutide reviews New insights on GLP-1 agonists—Ozempic, Wegovy, Mounjaro, and more (AMA 64 sneak peek) Peter Vosler, MD, PhD, FACS,

A five-year experiment reportedly aims to expand access to blockbuster GLP1 drugs for obesity, something advocates have sought for years

New research details improved liver health and reduced heart disease risk.

Learn what to do if you miss a dose

Theres not enough research to know for sure if and when its safe to take GLP-1s after giving birth

Track GLP-1 shots, pills, weight, food, and progress with Pep

The data supports continued use in: Type 2 diabetes Obesity and metabolic syndrome Patients with cardiometabolic risk factors Reasonable caution is still appropriate in individuals with: Active pancreatitis Recurrent idiopathic pancreatitis Severe hypertriglyceridemia until corrected